Neuroprotective Effects of Dexamethasone in a Neuromelanin-Driven Parkinson's Disease Model.

Parkinson's disease (PD) is characterized by the progressive loss of dopaminergic neurons in the substantia nigra that primarily affects movement control. Neuroinflammation plays a pivotal role in driving the disease's progression. The persistent inflammatory state in the brain exacerbates neuronal damage, creating a cycle that perpetuates the neurodegenerative process.

Preconditions for Including the Effects of Urease and Nitrification Inhibitors in Emission Inventories.

Urease and nitrification inhibitors can reduce ammonia and greenhouse gas emissions from fertilizers and manure but their effectiveness depends on the conditions under which they are used. Consequently, it is essential for the credibility of emission reductions reported in regulatory emission inventories that their effectiveness is assessed under real-world conditions and not just in the laboratory. Here, we specify the criteria we consider necessary before the effects of inhibitors are included in regulatory emission inventories.

Biomathematical model to analyze the transmission dynamics of Covid-19: Case study, Santiago de Cali, Colombia.

The Covid-19 pandemic has challenged both the scientific community and government authorities in Colombia. Both sectors are collaborating to understand the transmission and spread of the virus and to establish control strategies. This study proposes a biomathematical model with difference equations to analyze the transmission of Covid-19 in Santiago de Cali from March 2020 to June 2022.

Curation and reporting of pathogenic genome-wide copy-number variants in a prenatal cell-free DNA screen.

Purpose: Advances in fetal fraction amplification in prenatal cell-free DNA screening now allow for high-resolution detection of copy-number variants (CNVs). However, approaches to interpreting CNVs as part of a primary screen are still evolving and require consensus. Here, we present a conservative, patient-centered framework for reporting fetal CNVs.

Risdiplam: therapeutic effects and tolerability in a small cohort of 6 adult type 2 and type 3 SMA patients.

Background: Risdiplam is a validated treatment for adult SMA patients, but clear guidelines concerning functional assessment at baseline and during the follow-up are still limited, especially in terms of sensible and validated outcome measures able to capture minimal changes in motor performances induced by therapy. The aim of this work is to describe the effect of Risdiplam on a cohort of 6 adult type 2 and type 3 SMA patients, using Motor Function Measure (MFM32) as a standardized scaleto quantify the motor improvements induced by therapy.

Results: Risdiplam at the dose of 5 mg/daily was administered to a population of 6 (4 F;2 M) type 2 (N = 4) and type 3 (N = 2), adult SMA patients.